News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Daiichi Sankyo Co Ltd. Buys 20 Percent Stake in Ranbaxy Laboratories
October 17, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TOKYO, Oct 17 (Reuters) - Japan's Daiichi Sankyo Co said on Friday it had completed the purchase of 20 percent in India's Ranbaxy Laboratories, part of its plan to obtain a majority holding in the generic drugmaker.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Asia
MORE ON THIS TOPIC
Job Trends
Biopharma cuts at manufacturing plants expected to affect 4,000+
October 29, 2026
·
5 min read
·
Angela Gabriel
Immuno-oncology
Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset
October 28, 2026
·
2 min read
·
Tristan Manalac
Earnings
Biogen notches 3rd straight quarter of growth thanks to newer products, Apellis
October 28, 2026
·
1 min read
·
Annalee Armstrong
Podcast
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
October 28, 2026
·
1 min read
·
Jef Akst
